HPV vaccines: Cochrane Centre’s complaint vs safety review failedA complaint against the EMA’s handling of a referral procedure relating to potential side effects of Sanofi/MSD’s HPV vaccine Gardasil and GSK’s HPV jab Cervarix promoted by the Nordic Cochrane … more ➔
CHMP upgrades Roche’s lung cancer drug AlecensaThe European Medicines Agency (EMA) has upgraded Roche’s Alecensa (Alectinib) from second-line to first-line treatment for patients with locally advanced of metastasing ALK-positive non-small cell lung … more ➔
InflaRX raises US$55m in Series D roundGerman infection specialist InflaRx (Jena) raised US$55m in a Series D financing co-led by Bain Capital Life Sciences LP, Cormorant Asset Management LLC and RA Capital Management LLC to finance … more ➔
Targovax reports 100% one-year survival in pancreatic cancer trial Norwegian Targovax ASA (Oslo) has reported tremendous safety, immunogenicity, and one-year survival data, of in the modified cohort of the TG01 trial in resected pancreatic cancer patients. more ➔
Sanofi invests €170m to expand flu jab facilitySanofi is investing €170m to expand its vaccine manufacturing site in Val de Reuil, France, which produces 900 million vaccine doses worldwide each year. more ➔
Researchers describe alternative psoriasis targetBritish researchers have identified interleukin 36 (IL-36) as a druggable proinflammatory driver of psoriasis. Because of its very targeted effects of antibodies directed against the cytokine they want … more ➔
Neurim tables Phase III data of insomnia drugGerman-Israeli Neurim Pharmaceuticals announced top line efficacy results of its insomnia drug PedPRM in children with autism spectrum disorders (ASD). more ➔
Erytech Pharma set to raise US$100m in IPO and private placementFrench cancer drug encapsulation specialist Erytech Pharma SA wants to raise US$100m (€85m) in an IPO at NASDAQ and a subsequent private placement outside Northern America to finance pivotal trials … more ➔
uniQure’s AMT-130 receives FDA Orphan Drug Designation in Huntington’s disease As first gene therapy ever, AMT-130 has been granted FDA Orphan Drug status in Huntington’s Disease. more ➔
Promethera Biosciences partners with Shibuya Corp Promethera Biosciences and Shibuya collaborate to establish a breakthrough cell therapy manufacturing platform. more ➔
